Post-SGO Update: From Today’s Evidence to Tomorrow’s Innovation in Endometrial Cancer.
WEST
Tuesday, May 13th
5:30 PM PST
EAST
Tuesday, May 13th
6:30 PM EST
Learning Objectives
- Summarize the evolving first-line treatment landscape in endometrial cancer, including the clinical rationale for immunotherapy-chemotherapy combinations across biomarker subgroups.
- Evaluate mature long-term efficacy and safety data presented at SGO 2026, with emphasis on durability of benefit, survival outcomes, and patient-centered considerations.
- Integrate current long-term evidence into clinical practice, informing treatment selection, sequencing, and patient discussions, while remaining mindful of emerging therapies and future research directions.
Why Attend?
- Decode the latest 4-year survival data and what it means today
- Navigate evolving treatment goals beyond palliation
- Optimize sequencing across biomarker-defined populations
- Tackle real-world challenges with expert guidance
- Engage in interactive discussion on real clinical cases
Event Co-Chairs
East Chair
Kim Ma
MD, CM, FRCPC
Dr. Ma is an assistant professor at McGill University, and hematologist-oncologist at the Jewish General Hospital, Montreal, Canada. Her current fields of interest are hereditary GI cancers, as well as system optimization. She is investigator in phase 1 to 3 clinical trials with a focus in GI, breast and gynecological cancers.
West Chair
Jenny Ko
MD, FRCPC
Jenny Ko is a medical oncologist at BC Cancer – Abbotsford. She is Clinical Associate Professor at UBC Faculty of Medicine. She sees patients with GU, gyne and lung cancers. She has interests in quality/process improvement, novel technology in cancer care, and health services research.
Speaker for both East and West
Waldo Jimenez
MD, MSc
Dr. Waldo Jimenez completed his degree in medicine at Universidad de Concepcion, Chile in 1997. He completed residency training in obstetrics and gynecology at Universidad Catolica, Chile in 2000. He then went on to complete a masters in clinical epidemiology at the University of Toronto in 2007, while also completing his fellowship in obstetrics and gynecology at the University of Toronto in 2008.
Dr. Jimenez was an assistant professor in the Department of Obstetrics & Gynecology, Universidad Catolica, Concpecion, Chile from 2000–05. He then became an assistant professor in the Department of Obstetrics & Gynecology at the University of Toronto, Credit Valley Hospital from 2008–10. Dr. Jimenez became an assistant professor in the Department of Obstetrics & Gynecology at McMaster University, Juravinski Cancer Centre in 2010, and since 2016 has held the rank of associate professor.
This session is part of a multi-channel educational series aimed at improving clinical confidence and patient care in the era of ALK inhibitor therapy
This program has been made possible through unrestricted support from GSK.